Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study

Tomoyuki Goya, Hisao Asamura, Hirokuni Yoshimura, Harubumi Kato, Kaoru Shimokata, Ryosuke Tsuchiya, Yasunori Sohara, Toshimichi Miya, Etsuo Miyaoka

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

For the scheduled future revision of the TNM staging system for lung cancer, it is important that the present 1997 version be evaluated in a large population. In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a questionnaire to 320 Japanese institutions regarding the prognosis and clinicopathological profiles of patients who underwent the resection for primary lung neoplasms in 1994. We compiled the data for 7408 patients from 303 institutions (94.7%). Among these, 6644 patients with non-small cell histology were studied in terms of prognosis. The 5-year survival rate of the entire group was 52.6%. The 5-year survival rates by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV (n = 147). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The 5-year survival rates by pathological (p-) stage were as follows: 79.5% for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 719) and 20.0% for IV (n = 259). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The survival curves of stages IB and IIA were almost superimposed in both c- and p-settings. These findings indicated that the present stages IB and IIA should be merged into the same stage category. Otherwise, the present TNM staging system seemed to well characterize the stage-specific prognosis in non-small cell lung cancer. The future revision should focus on the subdivision of stages I and II.

Original languageEnglish
Pages (from-to)227-234
Number of pages8
JournalLung Cancer
Volume50
Issue number2
DOIs
Publication statusPublished - 2005 Nov
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Registries
Lung Neoplasms
Japan
Survival Rate
Neoplasm Staging
Histology
Survival
Population

Keywords

  • Lung cancer
  • Prognosis
  • Stage
  • Surgery
  • Survival
  • TNM classification

ASJC Scopus subject areas

  • Oncology

Cite this

Prognosis of 6644 resected non-small cell lung cancers in Japan : A Japanese lung cancer registry study. / Goya, Tomoyuki; Asamura, Hisao; Yoshimura, Hirokuni; Kato, Harubumi; Shimokata, Kaoru; Tsuchiya, Ryosuke; Sohara, Yasunori; Miya, Toshimichi; Miyaoka, Etsuo.

In: Lung Cancer, Vol. 50, No. 2, 11.2005, p. 227-234.

Research output: Contribution to journalArticle

Goya, T, Asamura, H, Yoshimura, H, Kato, H, Shimokata, K, Tsuchiya, R, Sohara, Y, Miya, T & Miyaoka, E 2005, 'Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study', Lung Cancer, vol. 50, no. 2, pp. 227-234. https://doi.org/10.1016/j.lungcan.2005.05.021
Goya, Tomoyuki ; Asamura, Hisao ; Yoshimura, Hirokuni ; Kato, Harubumi ; Shimokata, Kaoru ; Tsuchiya, Ryosuke ; Sohara, Yasunori ; Miya, Toshimichi ; Miyaoka, Etsuo. / Prognosis of 6644 resected non-small cell lung cancers in Japan : A Japanese lung cancer registry study. In: Lung Cancer. 2005 ; Vol. 50, No. 2. pp. 227-234.
@article{4648e1beabb64998839e7062fa90241e,
title = "Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study",
abstract = "For the scheduled future revision of the TNM staging system for lung cancer, it is important that the present 1997 version be evaluated in a large population. In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a questionnaire to 320 Japanese institutions regarding the prognosis and clinicopathological profiles of patients who underwent the resection for primary lung neoplasms in 1994. We compiled the data for 7408 patients from 303 institutions (94.7{\%}). Among these, 6644 patients with non-small cell histology were studied in terms of prognosis. The 5-year survival rate of the entire group was 52.6{\%}. The 5-year survival rates by clinical (c-) stage were as follows: 72.1{\%} for IA (n = 2423), 49.9{\%} for IB (n = 1542), 48.7{\%} for IIA (n = 150), 40.6{\%} for IIB (n = 746), 35.8{\%} for IIIA (n = 1270), 28.0{\%} for IIIB (n = 366) and 20.8{\%} for IV (n = 147). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The 5-year survival rates by pathological (p-) stage were as follows: 79.5{\%} for IA (n = 2009), 60.1{\%} for IB (n = 1418), 59.9{\%} for IIA (n = 232), 42.2{\%} for IIB (n = 757), 29.8{\%} for IIIA (n = 1250), 19.3{\%} for IIIB (n = 719) and 20.0{\%} for IV (n = 259). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The survival curves of stages IB and IIA were almost superimposed in both c- and p-settings. These findings indicated that the present stages IB and IIA should be merged into the same stage category. Otherwise, the present TNM staging system seemed to well characterize the stage-specific prognosis in non-small cell lung cancer. The future revision should focus on the subdivision of stages I and II.",
keywords = "Lung cancer, Prognosis, Stage, Surgery, Survival, TNM classification",
author = "Tomoyuki Goya and Hisao Asamura and Hirokuni Yoshimura and Harubumi Kato and Kaoru Shimokata and Ryosuke Tsuchiya and Yasunori Sohara and Toshimichi Miya and Etsuo Miyaoka",
year = "2005",
month = "11",
doi = "10.1016/j.lungcan.2005.05.021",
language = "English",
volume = "50",
pages = "227--234",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Prognosis of 6644 resected non-small cell lung cancers in Japan

T2 - A Japanese lung cancer registry study

AU - Goya, Tomoyuki

AU - Asamura, Hisao

AU - Yoshimura, Hirokuni

AU - Kato, Harubumi

AU - Shimokata, Kaoru

AU - Tsuchiya, Ryosuke

AU - Sohara, Yasunori

AU - Miya, Toshimichi

AU - Miyaoka, Etsuo

PY - 2005/11

Y1 - 2005/11

N2 - For the scheduled future revision of the TNM staging system for lung cancer, it is important that the present 1997 version be evaluated in a large population. In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a questionnaire to 320 Japanese institutions regarding the prognosis and clinicopathological profiles of patients who underwent the resection for primary lung neoplasms in 1994. We compiled the data for 7408 patients from 303 institutions (94.7%). Among these, 6644 patients with non-small cell histology were studied in terms of prognosis. The 5-year survival rate of the entire group was 52.6%. The 5-year survival rates by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV (n = 147). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The 5-year survival rates by pathological (p-) stage were as follows: 79.5% for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 719) and 20.0% for IV (n = 259). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The survival curves of stages IB and IIA were almost superimposed in both c- and p-settings. These findings indicated that the present stages IB and IIA should be merged into the same stage category. Otherwise, the present TNM staging system seemed to well characterize the stage-specific prognosis in non-small cell lung cancer. The future revision should focus on the subdivision of stages I and II.

AB - For the scheduled future revision of the TNM staging system for lung cancer, it is important that the present 1997 version be evaluated in a large population. In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a questionnaire to 320 Japanese institutions regarding the prognosis and clinicopathological profiles of patients who underwent the resection for primary lung neoplasms in 1994. We compiled the data for 7408 patients from 303 institutions (94.7%). Among these, 6644 patients with non-small cell histology were studied in terms of prognosis. The 5-year survival rate of the entire group was 52.6%. The 5-year survival rates by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV (n = 147). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The 5-year survival rates by pathological (p-) stage were as follows: 79.5% for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 719) and 20.0% for IV (n = 259). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The survival curves of stages IB and IIA were almost superimposed in both c- and p-settings. These findings indicated that the present stages IB and IIA should be merged into the same stage category. Otherwise, the present TNM staging system seemed to well characterize the stage-specific prognosis in non-small cell lung cancer. The future revision should focus on the subdivision of stages I and II.

KW - Lung cancer

KW - Prognosis

KW - Stage

KW - Surgery

KW - Survival

KW - TNM classification

UR - http://www.scopus.com/inward/record.url?scp=21644486386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644486386&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.05.021

DO - 10.1016/j.lungcan.2005.05.021

M3 - Article

C2 - 16061304

AN - SCOPUS:21644486386

VL - 50

SP - 227

EP - 234

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -